With easy comparisons to a year ago in some cases, growth was generally strong across the markets covered by BDSA in April. Strength in pre-rolls was a major factor. In this review, we will look at the markets one-by-one, beginning with the more mature Western markets and then concluding with the newer Eastern markets.
BDSA provides coverage for Arizona, California, Colorado, Nevada and Oregon. In April, growth ranged from 24% in Oregon to 129% in Nevada compared to a year ago.
Arizona transitioned to adult-use in late January, but this is the first month that BDSA included adult-use sales. Total cannabis sales grew 68% to $124.9 million, with adult-use representing $52.8 million. Medical cannabis sales fell 17% to $72.1 million. Growth was strong across all categories, but the highest growth by far was in pre-rolls, which gained 156%.
Sales soared 42% in April to $356.8 million, growth that was by far the strongest since the pandemic. It may be slightly overstated due to a dip in April a year ago from March. Flower grew in line with overall sales as did ingestibles, while concentrates were slower at 32% and pre-rolls were much stronger at 93%. The strength in pre-rolls is partially related to the dip a year ago when the pandemic was in its early days.
Colorado cannabis sales gained 36%, rising 2% sequentially to $202.8 million. Like the other Western states, pre-rolls led the way, up 72%. Ingestibles were very strong at +62%. Like pre-rolls, this category had declined as the tourists left the state a year ago. Flower grew a solid 21%.
Nevada had a massive decline a year ago as the Strip closed, so the 129% growth to